Selective Depletion of Tumor-Associated Macrophages Enhances Anti-Tumor Immunity in Pancreatic Cancer

Study of immunotherapeutic for pancreatic ductal adenocarcinoma (PDAC) remains a major issue currently. Tumor-associated macrophages (TAMs) represent a dominant immune population within tumor and play critical pro-tumor roles. Hence, targeting TAMs has emerged as a promising therapeutic strategy. Advances in single-cell transcriptomics have further revealed substantial macrophage heterogeneity within tumors, identifying distinct subsets with divergent functional roles. Therefore, selectively eliminating pro-tumorigenic macrophage while preserving beneficial populations represents a potentially more effective therapeutic approach for enhancing anti-PDAC immunity.